Skip to content
Advertisement
Boston Scientific prices $3 billion and €4.25 billion notes

Boston Scientific prices $3 billion and €4.25 billion notes

Proceeds are earmarked for the cash consideration in the Penumbra, Inc. acquisition, with closing set for December 1, 2026.

Key takeaways

  • USD Offering includes notes due 2029, 2031, 2033 and 2036, with rates from 5.375% to 5.875%.
  • Euro Offering includes Floating Rate Notes due 2028 and fixed-rate notes due 2028 through 2046.
  • Net proceeds intended to finance cash consideration for the acquisition of Penumbra, Inc., with the Offerings not conditioned on that acquisition.

The Boston Scientific financing covers $3 billion of US dollar notes and €4,250,000,000 of euro notes, Boston Scientific Corporation said on Nov. 19, 2026.

According to the release, the USD Notes include $1 billion of 5.375% Senior Notes due 2029 and $750 million of 5.500% Senior Notes due 2031. The rest are $750 million of 5.750% Senior Notes due 2033 and $500 million of 5.875% Senior Notes due 2036.

American Medical Systems Europe B.V., the company’s indirect wholly owned finance subsidiary, priced the euro notes, the release said. They include €500,000,000 of Floating Rate Notes due 2028 and €500,000,000 of 3.875% Senior Notes due 2028. Fixed-rate tranches follow: €750,000,000 of 4.125% notes due 2030 and €750,000,000 of 4.500% notes due 2034. The final tranches are €1,000,000,000 of 4.750% notes due 2038 and €750,000,000 of 5.125% notes due 2046.

Advertisement

Boston Scientific financing: the details

Instrument US dollar-denominated senior notes and euro-denominated senior and floating rate notes
Size $3 billion (USD Offering) and €4,250,000,000 (Euro Offering)
Use of proceeds Finance cash consideration for the acquisition of Penumbra, Inc. and related fees and expenses; any remainder for general corporate purposes
Closing date December 1, 2026, subject to customary closing conditions
  • The Euro Notes will be fully and unconditionally guaranteed by the Company.
  • Neither Offering is conditioned upon the completion of the other Offering.

The company said it will combine the proceeds with short-term borrowings and/or borrowings under its credit agreement(s) and cash on hand. Every series except the Floating Rate Notes faces a special mandatory redemption at 101% of principal, plus accrued and unpaid interest, if the Penumbra Acquisition is not completed by the applicable end date. The same redemption applies if the issuer notifies the trustee that the company will not pursue the deal. The joint book-running managers for the USD Offering are BofA Securities, Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC.

Background to the Boston Scientific financing

Boston Scientific describes itself as a global medical technology leader for more than 45 years, based in Marlborough, Mass. and listed on the NYSE under BSX. Its devices and therapies help physicians diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological and urological conditions, the company said.

Analysis

The two offerings put long-dated committed funding in place for the cash consideration in the Penumbra, Inc. acquisition. Together with borrowings and cash on hand, they could reduce the financing uncertainty around the deal. Maturities run from 2028 to 2046, which suggests the company is spreading repayment over nearly two decades.

The special mandatory redemption at 101% ties most of the notes to the Penumbra Acquisition actually closing. That deal, not the notes themselves, is likely the larger open question for holders of BSX. The cybersecurity incident first reported on August 26, 2026 remains listed among the company’s risk factors.

What to watch

  • December 1, 2026: Closing of the note offerings. Closing delivers the proceeds intended to fund the Penumbra Acquisition.
  • Completion of the Penumbra Acquisition. Failure to complete by the end date triggers a 101% special mandatory redemption of most series.

The crypto angle

More market coverage: Crypto Briefing Markets

Source: Boston Scientific, 2026-11-20 01:45 UTC

Disclosure: This article was edited by Vivian Nguyen. For more information on how we create and review content, see our Editorial Policy.